In recognition of Rare Disease Day 2026, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that its NETHERTON NOW awareness campaign has achieved nearly 2 million video views and more than 24 million impressions globally. The campaign, launched in February 2025, aims to amplify the voices of patients, caregivers, and clinicians impacted by Netherton Syndrome, a rare genetic skin disorder caused by mutations in the SPINK5 gene. The condition leads to excessive skin shedding, chronic inflammation, recurrent infections, and can be life-threatening, particularly in infancy.
Rare Disease Day, observed annually on the last day of February, was established in 2008 by EURORDIS to raise awareness of rare conditions. The NETHERTON NOW campaign has resonated strongly, with individuals who previously lived in silence now sharing their stories. Denise Carter, Co-Founder and COO of Quoin, stated, "Nearly 2 million video views and more than 24 million impressions later, what stands out most is the courage of the patients and families who chose to share their experiences."
The campaign recently released a video titled "If There Was a Cure," featuring patients and families reflecting on what meaningful treatment progress would mean. The video can be viewed at https://youtu.be/AIcGZQEumF0?si=5d226QrYKR3m-hHC. Dr. Michael Myers, CEO of Quoin, emphasized that growing awareness must be accompanied by action, including advancing clinical research and pursuing regulatory pathways. Quoin's lead investigational candidate, QRX003, is currently in late-stage pivotal clinical trials for Netherton Syndrome.
The NETHERTON NOW campaign underscores the unmet medical needs of the Netherton Syndrome community. For more information about Rare Disease Day, visit www.rarediseaseday.org. To learn more about Netherton Syndrome and the campaign, visit https://nethertonnow.com.
